The grades of 10 Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, Amgen Inc. (AMGN) pushes up from a C to a B rating. Amgen Inc. discovers, develops, manufactures, and markets medicines for serious illnesses. The company also gets A’s in earnings growth and return on equity. For more information, get Portfolio Grader’s complete analysis of AMGN stock.
This is a strong week for Gilead Sciences, Inc. (GILD). The company’s rating climbs to B from the previous week’s C. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The company also gets A’s in earnings growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of GILD stock.
Neurocrine Biosciences, Inc. (NBIX) shows solid improvement this week. The company’s rating rises from a C to a B. Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Five Prime Therapeutics, Inc. (FPRX) earns a A this week, jumping up from last week’s grade of B. The company also gets A’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of FPRX stock.
Ascendis Pharma A/S Sponsored ADR (ASND) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of ASND stock.
This week, Xencor, Inc.’s (XNCR) ratings are up from a C last week to a B. The company also gets A’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of XNCR stock.
Akebia Therapeutics, Inc. (AKBA) gets a higher grade this week, advancing from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of AKBA stock.
MiMedx Group, Inc.’s (MDXG) ratings are looking better this week, moving up to a B from last week’s C. MiMedx Group, Inc. operates as a medical device company. The company also gets A’s in sales growth, operating margin growth, earnings growth, earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of MDXG stock.
Spectrum Pharmaceuticals, Inc. (SPPI) improves from a C to a B rating this week. Spectrum Pharmaceuticals, Inc. is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. For more information, get Portfolio Grader’s complete analysis of SPPI stock.
The rating of Anavex Life Sciences Corp. (AVXL) moves up this week, rising from a B to a A. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of AVXL stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
